Opipramol
(Synonyms: 奥匹哌醇; Ensidon; G-33040) 目录号 : GC46010
A σ receptor ligand
Cas No.:315-72-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Opipramol is a sigma-1 (σ1) and σ2 receptor ligand.1 It binds to σ1 and σ2 receptors in guinea pig brain membrane preparations (IC50s = 7 and 56 nM, respectively). It is selective for σ1 and σ2 over histamine H2, dopamine D1, α1- and α2-adrenergic, and muscarinic M1 receptors (IC50s = 4,300, 900, 200, 6,100, and 3,300 nM, respectively) and has no effect on serotonin (5-HT) or norepinephrine uptake (IC50s = >10,000 nM for both), but does bind to histamine H1 and dopamine D2 receptors (IC50s = 12 and 120 nM, respectively), as well as the 5-HT receptor subtype 5-HT2 (IC50 = 120 nM). Opipramol (0.01 mg/kg) increases social interaction time in a social exploration test in rats, indicating anxiolytic-like activity. It also decreases immobility time in the forced swim test in rats, indicating antidepressant-like activity, when administered at a dose of 10 mg/kg.
|1. MÜller, W.E., Siebert, B., Holoubek, G., et al. Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand. Pharmacopsychiatry 37(Suppl 3), S189-S197 (2004).
| Cas No. | 315-72-0 | SDF | |
| 别名 | 奥匹哌醇; Ensidon; G-33040 | ||
| Canonical SMILES | OCCN(CC1)CCN1CCCN2C3=CC=CC=C3C=CC4=CC=CC=C42 | ||
| 分子式 | C23H29N3O | 分子量 | 363.5 |
| 溶解度 | Acetonitrile: slightly soluble,Chloroform: slightly soluble,Methanol: slightly soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.751 mL | 13.7552 mL | 27.5103 mL |
| 5 mM | 0.5502 mL | 2.751 mL | 5.5021 mL |
| 10 mM | 0.2751 mL | 1.3755 mL | 2.751 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
[Update Opipramol]
Fortschr Neurol Psychiatr 2017 Mar;85(3):139-145.PMID:28320023DOI:10.1055/s-0043-100762.
Opipramol was developed in the 1960s as an antidepressant and has chemical similarities with tricyclic antidepressants. Pharmacodynamic properties with absent reuptake inhibition of serotonin and noradrenaline and agonism at sigma receptors distinguish Opipramol from tricyclics. Furthermore, antidepressive effects are smaller than the anxiolytic ones. The mechanism of action of Opipramol is currently not sufficiently understood. Agonistic effects at sigma receptors have been linked with therapeutic effects. Excessive hepatic metabolism (primarily via CYP2D6) should be considered, particularly in patients with impaired hepatic function and polypharmacy. The available clinical data suggest good tolerability and safety within the approved dose range. Mild disturbances of vigilance and anticholinergic adverse events are the predominant side effects. In Germany, Opipramol is approved for the treatment of somatoform disorders and generalized anxiety disorder, and there is sufficient evidence for the efficacy of Opipramol in these disorders. The agent is still prescribed very often in Germany, yet plays a minor role in the clinical as well as scientific setting. In view of the limited availability of (pharmacologic) treatment options for generalized anxiety disorder and particularly somatoform disorders, Opipramol should be considered in the treatment of these entities.
Opipramol
Acta Crystallogr Sect E Struct Rep Online 2011 Jul 1;67(Pt 7):o1598.PMID:21837006DOI:10.1107/S1600536811021131.
2-{4-[3-(5H-dibenz[b,f]azepin-5-yl)prop-yl]piperazin-1-yl}ethanol), C(23)H(29)N(3)O, the 5H-dibenz[b,f]azepine and piperazine rings adopt boat and chair conformations, respectively, and the overall shape of the fused ring part of the molecule is a butterfly. In the crystal, O-H⋯N and C-H⋯O hydrogen bonds link the mol-ecules into a layer parallel to the bc plane.
Opipramol dihydro-chloride
Acta Crystallogr Sect E Struct Rep Online 2011 Nov;67(Pt 11):o2994-5.PMID:22220014DOI:10.1107/S1600536811042280.
4-{3-[2-aza-tricyclo-[9.4.0.0(3,8)]penta-deca-1(15),3,5,7,11,13-hexaen-2-yl]prop-yl}-1-(2-hy-droxy-eth-yl)piperazine-1,4-diium dichloride), C(23)H(31)N(3)O(+)·2Cl(-), is the dihydro-chloride of a piperazine derivative bearing a bulky 3-(5H-dibenz[b,f]azepin-5-yl)propyl substituent. Protonation took place on both N atoms of the piperazine unit. The diaza-cyclo-hexane ring adopts a chair conformation. N-H⋯Cl, O-H⋯Cl and C-H⋯Cl hydrogen bonding as well as C-H⋯O contacts connect the components into a three-dimensional network in the crystal. Two C-H⋯π contacts are also observed.
Opipramol dipicrate
Acta Crystallogr Sect E Struct Rep Online 2010 Jul 10;66(Pt 8):o1979-80.PMID:21588296DOI:10.1107/S1600536810026565.
In the crystal structure of the title compound, C(23)H(31)N(3)O(2+)·2C(6)H(2)N(3)O(7) (-), {systematic name: 1-[3-(5H-dibenz[b,f]azepin-5-yl)prop-yl]-4-(2-hy-droxy-eth-yl)piperazine-1,4-diium bis-(2,4,6-trinitro-phrenolate)} the piperazine group in the Opipramol dication is protonated at both N atoms. Each picrate anion inter-acts with the protonated N atom in the cation through a bifurcated N-H⋯O hydrogen bond, forming an R(2) (1)(6) ring motif. In the cation, the dihedral angle between the mean planes of the two benzene rings is 50.81 (8) Å. Inter-molecular O-H⋯O and weak C-H⋯O hydrogen bonds, and weak π-ring and π-π stacking inter-actions dominate the crystal packing.
Efficacy of treatments for anxiety disorders: a meta-analysis
Int Clin Psychopharmacol 2015 Jul;30(4):183-92.PMID:25932596DOI:10.1097/YIC.0000000000000078.
To our knowledge, no previous meta-analysis has attempted to compare the efficacy of pharmacological, psychological and combined treatments for the three main anxiety disorders (panic disorder, generalized anxiety disorder and social phobia). Pre-post and treated versus control effect sizes (ES) were calculated for all evaluable randomized-controlled studies (n = 234), involving 37,333 patients. Medications were associated with a significantly higher average pre-post ES [Cohen's d = 2.02 (1.90-2.15); 28,051 patients] than psychotherapies [1.22 (1.14-1.30); 6992 patients; P < 0.0001]. ES were 2.25 for serotonin-noradrenaline reuptake inhibitors (n = 23 study arms), 2.15 for benzodiazepines (n = 42), 2.09 for selective serotonin reuptake inhibitors (n = 62) and 1.83 for tricyclic antidepressants (n = 15). ES for psychotherapies were mindfulness therapies, 1.56 (n = 4); relaxation, 1.36 (n = 17); individual cognitive behavioural/exposure therapy (CBT), 1.30 (n = 93); group CBT, 1.22 (n = 18); psychodynamic therapy 1.17 (n = 5); therapies without face-to-face contact (e.g. Internet therapies), 1.11 (n = 34); eye movement desensitization reprocessing, 1.03 (n = 3); and interpersonal therapy 0.78 (n = 4). The ES was 2.12 (n = 16) for CBT/drug combinations. Exercise had an ES of 1.23 (n = 3). For control groups, ES were 1.29 for placebo pills (n = 111), 0.83 for psychological placebos (n = 16) and 0.20 for waitlists (n = 50). In direct comparisons with control groups, all investigated drugs, except for citalopram, Opipramol and moclobemide, were significantly more effective than placebo. Individual CBT was more effective than waiting list, psychological placebo and pill placebo. When looking at the average pre-post ES, medications were more effective than psychotherapies. Pre-post ES for psychotherapies did not differ from pill placebos; this finding cannot be explained by heterogeneity, publication bias or allegiance effects. However, the decision on whether to choose psychotherapy, medications or a combination of the two should be left to the patient as drugs may have side effects, interactions and contraindications.